Baird Reiterates Outperform on PTC Therapeutics, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has reiterated an Outperform rating for PTC Therapeutics, maintaining a price target of $44.
October 08, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty has reiterated an Outperform rating for PTC Therapeutics, maintaining a price target of $44. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $44 price target by a reputable analyst suggests a positive outlook for PTC Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100